Kyle Baylous, Brandon Kovarovic, Salwa Anam, Ryan Helbock, Marvin Slepian, Danny Bluestein
{"title":"Thrombogenic Risk Assessment of Transcatheter Prosthetic Heart Valves Using a Fluid-Structure Interaction Approach","authors":"Kyle Baylous, Brandon Kovarovic, Salwa Anam, Ryan Helbock, Marvin Slepian, Danny Bluestein","doi":"arxiv-2406.12156","DOIUrl":null,"url":null,"abstract":"Prosthetic heart valve interventions such as TAVR have surged over the past\ndecade, but the associated complication of long-term, life-threatening\nthrombotic events continues to undermine patient outcomes. Thus, improving\nthrombogenic risk analysis of TAVR devices is crucial. In vitro studies for\nthrombogenicity are typically difficult to perform. However, revised ISO\ntesting standards include computational testing for thrombogenic risk\nassessment of cardiovascular implants. We present a fluid-structure interaction\n(FSI) approach for assessing thrombogenic risk of prosthetic heart valves. An FSI framework was implemented via the incompressible computational fluid\ndynamics multi-physics solver of the Ansys LS-DYNA software. The numerical\nmodeling approach for flow analysis was validated by comparing the derived flow\nrate of the 29-mm CoreValve device from benchtop testing and orifice areas of\ncommercial TAVR valves in the literature to in silico results. Thrombogenic\nrisk was analyzed by computing stress accumulation (SA) on virtual platelets\nseeded in the flow fields via Ansys EnSight. The integrated FSI-thrombogenicity\nmethodology was subsequently employed to examine hemodynamics and thrombogenic\nrisk of TAVR devices with two approaches: 1) engineering optimization and 2)\nclinical assessment. Our methodology can be used to improve the thromboresistance of prosthetic\nvalves from the initial design stage to the clinic. It allows for unparalleled\noptimization of devices, uncovering key TAVR leaflet design parameters that can\nbe used to mitigate thrombogenic risk, in addition to patient-specific modeling\nto evaluate device performance. This work demonstrates the utility of advanced\nin silico analysis of TAVR devices that can be utilized for thrombogenic risk\nassessment of other blood recirculating devices.","PeriodicalId":501572,"journal":{"name":"arXiv - QuanBio - Tissues and Organs","volume":"359 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Tissues and Organs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2406.12156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Prosthetic heart valve interventions such as TAVR have surged over the past
decade, but the associated complication of long-term, life-threatening
thrombotic events continues to undermine patient outcomes. Thus, improving
thrombogenic risk analysis of TAVR devices is crucial. In vitro studies for
thrombogenicity are typically difficult to perform. However, revised ISO
testing standards include computational testing for thrombogenic risk
assessment of cardiovascular implants. We present a fluid-structure interaction
(FSI) approach for assessing thrombogenic risk of prosthetic heart valves. An FSI framework was implemented via the incompressible computational fluid
dynamics multi-physics solver of the Ansys LS-DYNA software. The numerical
modeling approach for flow analysis was validated by comparing the derived flow
rate of the 29-mm CoreValve device from benchtop testing and orifice areas of
commercial TAVR valves in the literature to in silico results. Thrombogenic
risk was analyzed by computing stress accumulation (SA) on virtual platelets
seeded in the flow fields via Ansys EnSight. The integrated FSI-thrombogenicity
methodology was subsequently employed to examine hemodynamics and thrombogenic
risk of TAVR devices with two approaches: 1) engineering optimization and 2)
clinical assessment. Our methodology can be used to improve the thromboresistance of prosthetic
valves from the initial design stage to the clinic. It allows for unparalleled
optimization of devices, uncovering key TAVR leaflet design parameters that can
be used to mitigate thrombogenic risk, in addition to patient-specific modeling
to evaluate device performance. This work demonstrates the utility of advanced
in silico analysis of TAVR devices that can be utilized for thrombogenic risk
assessment of other blood recirculating devices.